US2008275007A1PendingUtilityA1

Charged phospholipid compositions and methods for their use

69
Individually held — no corporate assignee on recordPriority: Jul 31, 2000Filed: Apr 21, 2008Published: Nov 6, 2008
Est. expiryJul 31, 2020(expired)· nominal 20-yr term from priority
Inventors:Daniel Sparks
A61K 31/683A61P 31/12A61P 39/02A61K 31/663A61K 31/685A61P 31/22A61P 31/04A61P 9/10A61K 31/66A61P 3/06A61P 7/02
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins.

Claims

exact text as granted — not AI-modified
1 . A method for clearing a virus or a bacterial endotoxin from the bloodstream of a mammal infected with the virus or a bacterium, the method consisting essentially of administering to said mammal a therapeutically effective amount of a negatively charged phospholipid for achieving removal of said virus or said endotoxin from the bloodstream of said mammal. 
     
     
         2 . The method of  claim 1 , wherein the mammal is a human. 
     
     
         3 . The method of  claim 1 , wherein said negatively charged phospholipid is phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, or phosphatidic acid, or any combination thereof. 
     
     
         4 . The method of  claim 1 , wherein said negatively charged phospholipid is phosphatidylinositol. 
     
     
         5 . The method of  claim 1 , wherein said negatively charged phospholipid is phosphatidylserine. 
     
     
         6 . The method of  claim 1 , wherein said negatively charged phospholipid is phosphatidylglycerol. 
     
     
         7 . The method of  claim 1 , wherein said negatively charged phospholipid is phosphatidic acid. 
     
     
         8 . The method of  claim 1 , wherein said negatively charged phospholipid is administered in a dose of 5 micromole to 100 micromole per kg body weight of the mammal. 
     
     
         9 . The method of  claim 1 , wherein said negatively charged phospholipid is administered in a dose of 5 micromole to 20 micromole per kg body weight of the mammal. 
     
     
         10 . The method of  claim 1 , wherein said negatively charged phospholipid is formulated as a food additive. 
     
     
         11 . The method of  claim 1 , wherein said negatively charged phospholipid is formulated as a medicament. 
     
     
         12 . The method of  claim 11 , wherein the medicament is administered orally, intranasally, transdermally, or by injection. 
     
     
         13 . The method of  claim 1 , wherein said negatively charged phospholipid is in the form of unilammellar vesicles, multilamellar vesicles, multilamellar sheets, dispersion, micellar solutions, emulsions, or microemulsions. 
     
     
         14 . The method of  claim 1 , wherein said negatively charged phospholipid is in the form of a powder. 
     
     
         15 . (canceled) 
     
     
         16 . The method of  claim 1 , wherein said virus belongs to the Herpes virus family. 
     
     
         17 . The method of  claim 16 , wherein said virus is cytomegalovirus (CMV). 
     
     
         18 - 20 . (canceled)

Join the waitlist — get patent alerts

Track US2008275007A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.